Vir Biotechnology. has filed a patent for antibodies that bind to the antigenic loop region of hepatitis B surface antigen (HBsAg) and effectively neutralize both hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections. The patent also covers the epitopes to which the antibodies bind, as well as the nucleic acids and cells involved in producing these antibodies. The invention has potential applications in the diagnosis, prevention, and treatment of hepatitis B and hepatitis D. GlobalData’s report on Vir Biotechnology gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Vir Biotechnology Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Vir Biotechnology, Peptide pharmacophores was a key innovation area identified from patents. Vir Biotechnology's grant share as of September 2023 was 18%. Grant share is based on the ratio of number of grants to total number of patents.

Antibodies for neutralizing hepatitis b and hepatitis d infection

Source: United States Patent and Trademark Office (USPTO). Credit: Vir Biotechnology Inc

A recently filed patent (Publication Number: US20230303663A1) describes an isolated antibody or antigen-binding fragment that can be used for treating hepatitis B and/or hepatitis D infections. The antibody or fragment includes specific amino acid sequences known as CDRH1, CDRH2, and CDRH3, as well as CDRL1, CDRL2, and CDRL3. The patent claims various combinations of these sequences, providing flexibility in the design of the antibody.

The antibody or fragment described in the patent also includes a heavy chain variable domain (VH) and a light chain variable domain (VL). These domains have amino acid sequences that are at least 95% identical to specific sequences listed in the patent. This high degree of identity ensures the effectiveness of the antibody in targeting the hepatitis B and/or hepatitis D infections.

Additionally, the patent claims that the antibody or fragment may include a Fc moiety, which can enhance its therapeutic properties. The antibody or fragment can be of human origin, making it potentially suitable for use in human patients.

The patent also covers different forms of the antibody or fragment, including purified antibodies, single chain antibodies, Fab, Fab', F(ab'),2, Fv, or scFv. These variations provide options for optimizing the antibody's properties and potential applications.

The patent further describes a nucleic acid molecule that encodes the antibody or fragment, which can be used for producing the antibody in a host cell. The nucleic acid molecule may be codon-optimized for efficient expression in the host cell.

Other aspects of the patent include a vector containing the nucleic acid molecule, a cell comprising the nucleic acid, a pharmaceutical composition comprising the antibody or fragment and a suitable carrier, and a kit containing the antibody or fragment along with one or more additional components such as a polymerase inhibitor, an interferon, or a checkpoint inhibitor.

Finally, the patent claims a method for treating hepatitis B and/or hepatitis D infections by administering an effective amount of the antibody or fragment to a patient. The method can be used in various scenarios, including chronic hepatitis B infections, patients who have received a liver transplant, non-immunized individuals, newborns, and patients undergoing or having undergone hemodialysis. The method may also involve the use of additional treatments such as polymerase inhibitors, interferons, or checkpoint inhibitors.

Overall, this patent describes a potentially valuable antibody or fragment for the treatment of hepatitis B and/or hepatitis D infections, offering various options for customization and potential therapeutic applications.

To know more about GlobalData’s detailed insights on Vir Biotechnology, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies